EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Organoid‐based two‐step drug screening for rapid identification of chemotherapy‐resistant oesophageal squamous cell carcinoma and alternative therapies

Chen-Ye Shao, Sheng Ju, Xin Tong, Kang Hu, Yu Li, Yi-Xian Zhu iD, Jian Yang, Chang Li iD, Yu-Feng Xie, Yuan Cui, Wei-Jun Deng, Cheng Ding und 2 weitere

Clinical and Translational Medicine · 2025

DOI: 10.1002/ctm2.70534 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2025. Verfasst von Chen-Ye Shao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Organoids, Drug Resistance, Neoplasm, Esophageal Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Postgraduate Research & Practice Innovation Program of Jiangsu Province, National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite guideline‐directed therapies, most patients with advanced oesophageal squamous cell carcinoma (ESCC) derive limited benefit and are unable to tolerate iterative treatment modifications. Therefore, timely identification of resistant cases and the provision of alternative therapeutic options are urgently needed.

Methods

A large‐scale patient‐derived organoid model was established from locally advanced patients with ESCC who underwent perioperative chemotherapy and was validated for consistency with the parental tumours through histopathological, genomic and transcriptomic analysis. A novel two‐step drug screening method based on growth rate inhibition (GR) was developed, and drug sensitivity results were compared with clinical outcomes. Additionally, in vivo assays were conducted to evaluate alternative therapies using the C max /GR100 index.

Results

ESCC organoids demonstrated high consistency with parental tumours in histopathology, genomics and transcriptomics. The two‐step drug screening method revealed a strong correlation with clinical responses (sensitivity 80%, specificity 85.7%, overall accuracy 83.3%) and significantly shortened the experimental timeline compared with the traditional drug screening method (23.08 ± 2.42 days vs. 45.75 ± 7.19 days, p < .001). Furthermore, we proposed a novel drug selection strategy based on C max /GR100 values, which provides a theoretical foundation for drug repurposing and offers alternative treatment options for patients resistant to TP (taxol + cisplatin) therapy, thereby facilitating precise re‐treatment in drug‐resistant subgroups.

Conclusions

This method exhibits strong clinical applicability, supporting more accurate and timely decision‐making in ESCC management. The C max /GR100‐based drug screening strategy can dynamically identify alternative sensitive drugs for patients who fail first‐line therapies, enabling precise re‐treatment. This approach provides a valuable tool for translating laboratory findings into clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal Squamous Cell CarcinomaOrganoidsDrug Resistance, NeoplasmEsophageal NeoplasmsHumansMaleFemaleDrug Screening Assays, AntitumorAnimalsAntineoplastic AgentsMiceMiddle Aged

Stichwörter der Autor:innen

drug screeningdrug sensitivityoesophageal squamous cell carcinomaprecision medicinetumour organoids

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Department of Thoracic Surgery, Institute of Minimally Invasive Thoracic Cancer Therapy and Translational Research, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Department of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.

ORCID-Profile: Yi-Xian Zhu, Chang Li, Jun Zhao

Förderung

  • The Postgraduate Research & Practice Innovation Program of Jiangsu Province
  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province
  • Suzhou Municipal Basic Research Special Project
  • The Boxi Cultivation Program Natural Science Foundation

Zitieren

APA

Shao, C. Y., Ju, S., Tong, X., Hu, K., Li, Y., Zhu, Y. X., Yang, J., Li, C., Xie, Y. F., Cui, Y., Deng, W. J., Ding, C., Qin, S. B., & Zhao, J. (2025). Organoid‐based two‐step drug screening for rapid identification of chemotherapy‐resistant oesophageal squamous cell carcinoma and alternative therapies. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70534

Vancouver

Shao CY, Ju S, Tong X, Hu K, Li Y, Zhu YX, et al. Organoid‐based two‐step drug screening for rapid identification of chemotherapy‐resistant oesophageal squamous cell carcinoma and alternative therapies. Clinical and Translational Medicine. 2025. doi:10.1002/ctm2.70534

BibTeX
@article{Shao2025,
  author = {Shao, Chen-Ye and Ju, Sheng and Tong, Xin and Hu, Kang and Li, Yu and Zhu, Yi-Xian and Yang, Jian and Li, Chang and Xie, Yu-Feng and Cui, Yuan and Deng, Wei-Jun and Ding, Cheng and Qin, Song-Bing and Zhao, Jun},
  title = {Organoid‐based two‐step drug screening for rapid identification of chemotherapy‐resistant oesophageal squamous cell carcinoma and alternative therapies},
  journal = {Clinical and Translational Medicine},
  year = {2025},
  doi = {10.1002/ctm2.70534}
}
Kostenlos starten →